A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

NCT07089706 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

832

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: mRNA-1283.251 Variant-containing Formulation

Sponsor

ModernaTX, Inc.